-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Assembly Biosciences, Lowers Price Target to $45

Benzinga·09/01/2026 14:49:45
Listen to the news
Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and lowers the price target from $53 to $45.